tirzepatide and concerta Dosage Chart & Dosing Guide for Weight Loss Weight Loss - Rejuvenescence Med

10.1016/j.molmet.2018.07.011 46

NICE guidance (NG28) on type 2 diabetes management recognises GLP-1 receptor agonists as effective second- or third-line therapies, particularly for patients with obesity or those requiring additional glycaemic control

Ruscoe JE, Rosario LA, Wang T, Gat L, Arifoglu P, Wolf CR et al

3 Start your weight loss journey We ship your medication direct to you, with support throughout your journey

Worth noting: adding GIP agonism (tirzepatide) appears to attenuate GLP-1-driven nausea rather than amplify it, consistent with the lower SURMOUNT-1 figure

In the SURMOUNT clinical trial program for obesity, participants achieved average weight loss of 15-21% of body weight depending on dose, significantly exceeding results with diet and exercise alone or other available pharmacotherapies